TCR2 Therapeutics Stock Forecast, Price & News

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view top-rated stocks.

How has TCR2 Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR shares have decreased by 38.9% and is now trading at $5.24.
View which stocks have been most impacted by COVID-19.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 1,300,000 shares, a drop of 15.0% from the October 14th total of 1,530,000 shares. Based on an average daily trading volume, of 778,700 shares, the days-to-cover ratio is currently 1.7 days. Currently, 3.6% of the company's shares are sold short.
View TCR2 Therapeutics' Short Interest.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for TCR2 Therapeutics.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.
View TCR2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

10 Wall Street analysts have issued 1-year price objectives for TCR2 Therapeutics' shares. Their forecasts range from $7.00 to $55.00. On average, they anticipate TCR2 Therapeutics' share price to reach $28.20 in the next year. This suggests a possible upside of 438.2% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:

• Garry E. Menzel, President, Chief Executive Officer & Director
• Mayur Ian Somaiya, Chief Financial Officer
• Robert Hofmeister, Chief Scientific Officer
• Alfonso Quintás-Cardama, Chief Medical Officer
• Peter Olagunju, Chief Technical Officer

Who are some of TCR2 Therapeutics' key competitors?

Some companies that are related to TCR2 Therapeutics include MeiraGTx (MGTX), Finch Therapeutics Group (FNCH), Cullinan Oncology (CGEM), Tenaya Therapeutics (TNYA), Forma Therapeutics (FMTX), Gritstone bio (GRTS), Sutro Biopharma (STRO), bluebird bio (BLUE), Immatics (IMTX), Aligos Therapeutics (ALGS), Osiris Therapeutics (OSIR), Aura Biosciences (AURA), Adaptimmune Therapeutics (ADAP), Graphite Bio (GRPH) and Ikena Oncology (IKNA).
View all of TCRR's competitors.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.76%), Wellington Management Group LLP (7.19%), ArrowMark Colorado Holdings LLC (3.18%), Geode Capital Management LLC (1.19%), Rothschild & Co. Asset Management US Inc. (0.91%) and Two Sigma Investments LP (0.84%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics.

Which major investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Altium Capital Management LP, Squarepoint Ops LLC, Citigroup Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for TCR2 Therapeutics or view top insider-selling stocks.

Which major investors are buying TCR2 Therapeutics stock?

TCRR stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Marshall Wace LLP, ArrowMark Colorado Holdings LLC, Caas Capital Management LP, Caption Management LLC, Trexquant Investment LP, Two Sigma Investments LP, and Oppenheimer & Co. Inc..
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $5.24.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $200.27 million. The company earns $-67.12 million in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 118 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

Where are TCR2 Therapeutics' headquarters?

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 949-5200 or via email at [email protected].